Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Upgrades
- Wedbush changed the rating for Toll Brothers Inc (NYSE:TOL) from Neutral to Outperform. In the first quarter, Toll Brothers showed an EPS of $0.41, compared to $0.76 from the year-ago quarter. The stock has a 52-week-high of $49.31 and a 52-week-low of $34.34. Toll Brothers's stock last closed at $37.86 per share.
- Raymond James changed the rating for Interface Inc (NASDAQ:TILE) from Underperform to Market Perform. For the fourth quarter, Interface had an EPS of $0.46, compared to year-ago quarter EPS of $0.41. The stock has a 52-week-high of $18.68 and a 52-week-low of $10.37. Interface's stock last closed at $16.16 per share.
- JP Morgan changed the rating for StoneCo Ltd (NASDAQ:STNE) from Neutral to Overweight. Interestingly, in the third quarter, StoneCo's EPS was $0.17. The stock has a 52-week-high of $45.72 and a 52-week-low of $23.15. StoneCo's stock last closed at $41.57 per share.
- JP Morgan upgraded the stock for Logitech International SA (NASDAQ:LOGI) from Neutral to Overweight. For the third quarter, Logitech International had an EPS of $0.84, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $48.83 and a 52-week-low of $35.70. Logitech International's stock last closed at $39.23 per share.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Downgrades
- For Continental Resources Inc (NYSE:CLR), KeyBanc downgraded the stock from Overweight to Sector Weight. For the fourth quarter, Continental Resources had an EPS of $0.55, compared to year-ago quarter EPS of $0.54. The stock has a 52-week-high of $52.03 and a 52-week-low of $20.66. Continental Resources's stock last closed at $20.78 per share.
- Credit Suisse changed the rating for Virgin Galactic Holdings Inc (NYSE:SPCE) from Outperform to Neutral. In the fourth quarter, Virgin Galactic Holdings earned ($0.37). The stock has a 52-week-high of $42.49 and a 52-week-low of $6.90. Virgin Galactic Holdings's stock last closed at $28.71 per share.
- Morgan Stanley changed the rating for Revolve Group Inc (NYSE:RVLV) from Overweight to Equal-Weight. Interestingly, in the fourth quarter, Revolve Group's EPS was $0.12. The stock has a 52-week-high of $48.36 and a 52-week-low of $14.35. Revolve Group's stock last closed at $16.65 per share.
- Morgan Stanley changed the rating for Virgin Galactic Holdings Inc (NYSE:SPCE) from Overweight to Equal-Weight. Interestingly, in the fourth quarter, Virgin Galactic Holdings's EPS was ($0.37). The stock has a 52-week-high of $42.49 and a 52-week-low of $6.90. Virgin Galactic Holdings's stock last closed at $28.71 per share.
Initiations
- Barclays initiated coverage on Molecular Templates Inc (NASDAQ:MTEM) with an Overweight rating. The price target for Molecular Templates is set at $22.00. Molecular Templates earned ($0.44) in the third quarter, compared to ($0.19) in the year-ago quarter. The stock has a 52-week-high of $18.38 and a 52-week-low of $4.51. Molecular Templates's stock last closed at $16.44 per share.
- Barclays initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS) with an Overweight rating. The price target for Gossamer Bio is set at $21.00. Gossamer Bio earned ($0.80) in the third quarter. The stock has a 52-week-high of $27.15 and a 52-week-low of $13.12. Gossamer Bio's stock last closed at $13.93 per share.
- Barclays initiated coverage on Gilead Sciences Inc (NASDAQ:GILD) with an Underweight rating. The price target for Gilead Sciences is set at $62.00. In the fourth quarter, Gilead Sciences showed an EPS of $1.30, compared to $1.44 from the year-ago quarter. The stock has a 52-week-high of $75.47 and a 52-week-low of $60.89. Gilead Sciences's stock last closed at $74.70 per share.
- With a rating of Overweight, Barclays initiated coverage on Applied Therapeutics Inc (NASDAQ:APLT). The price target is set at $64.00 for Applied Therapeutics. In the third quarter, Applied Therapeutics showed an EPS of ($0.63), compared to ($0.78) from the year-ago quarter. The stock has a 52-week-high of $57.39 and a 52-week-low of $7.95. Applied Therapeutics's stock last closed at $41.70 per share.
- With a rating of Equal-Weight, Barclays initiated coverage on Bristol-Myers Squibb Company (NYSE:BMY). The price target is set at $69.00 for Bristol-Myers Squibb. In the fourth quarter, Bristol-Myers Squibb showed an EPS of $1.22, compared to $0.94 from the year-ago quarter. The stock has a 52-week-high of $68.34 and a 52-week-low of $42.48. Bristol-Myers Squibb's stock last closed at $62.02 per share.
- Barclays initiated coverage on Biogen Inc (NASDAQ:BIIB) with an Overweight rating. The price target for Biogen is set at $389.00. Biogen earned $8.34 in the fourth quarter, compared to $6.99 in the year-ago quarter. The stock has a 52-week-high of $374.99 and a 52-week-low of $215.78. Biogen's stock last closed at $327.45 per share.
- With a rating of Equal-Weight, Barclays initiated coverage on Pfizer Inc (NYSE:PFE). The price target is set at $36.00 for Pfizer. Pfizer earned $0.55 in the fourth quarter, compared to $0.64 in the year-ago quarter. The stock has a 52-week-high of $44.56 and a 52-week-low of $33.71. Pfizer's stock last closed at $34.72 per share.
- Barclays initiated coverage on Acceleron Pharma Inc (NASDAQ:XLRN) with an Overweight rating. The price target for Acceleron Pharma is set at $107.00. Acceleron Pharma earned \ No EPS Value in the fourth quarter, compared to ($0.75) in the year-ago quarter. The stock has a 52-week-high of $95.95 and a 52-week-low of $37.01. Acceleron Pharma's stock last closed at $87.36 per share.
- With a rating of Equal-Weight, Barclays initiated coverage on AbbVie Inc (NYSE:ABBV). The price target is set at $97.00 for AbbVie. For the fourth quarter, AbbVie had an EPS of $2.21, compared to year-ago quarter EPS of $1.90. The stock has a 52-week-high of $97.86 and a 52-week-low of $62.66. AbbVie's stock last closed at $88.45 per share.
- H.C. Wainwright initiated coverage on LSI Industries Inc (NASDAQ:LYTS) with a Buy rating. The price target for LSI Industries is set at $9.00. For the second quarter, LSI Industries had an EPS of $0.06, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $7.30 and a 52-week-low of $2.48. LSI Industries's stock last closed at $6.49 per share.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.